Progesterone plays an essential role in the maintenance of the endometrium; it prepares the endometrium for pregnancy, promotes decidualization, and inhibits estrogen-dependent proliferation. Progesterone function is often dysregulated in endometrial disease states. In addition, the PI3K/AKT signaling pathway is often overactive in endometrial pathologies and promotes the survival and proliferation of the diseased cells. Understanding how AKT influences progesterone action is critical in improving hormone-based therapies in endometrial pathologies. Here, we summarize recent studies investigating the crosstalk between the AKT pathway and progesterone receptor function in endometriosis and endometrial cancer.
INTRODUCTION
Progesterone causes numerous changes in the human uterus for the sole purpose of preparing and maintaining pregnancy. When there is no pregnancy, which is usually the majority of time during a woman's reproductive years, the endometrium sloughs off and prepares for regeneration the next month [1] . The response of the endometrium to dynamically changing estrogen and progesterone levels is one that is unique from the rest of the organ systems, and one that requires strict timing and synchronization to allow for the successful establishment of pregnancy [2] . In a timed sequence of events, the endometrium proliferates in response to rising levels of estradiol and then differentiates and remodels in response to progesterone [3] . Estrogen and progesterone action is primarily mediated through their receptors, estrogen receptor (ER) and progesterone receptor (PR). Studies have shown that controlled action of these hormone receptors involves a complex network of interactions with signaling pathways, downstream effectors, transcription factors, coregulators, chromatin remodeling factors, and DNA [4] . Aberrations in this regulation can lead to an endometrium that is refractory to implantation, or can manifest as diseases of the uterus, such as endometriosis and endometrial cancer. For example, the AKT signaling pathway is hyperactivated in endometrial cancer because of prevalent PTEN mutations as well as mutations in PI3K and AKT [5] . In endometriosis, the AKT pathway is overactive most likely because of the inflammatory and hormonal nature of the disease [6, 7] . Studies of AKT in endometriosis and endometrial cancer using in vitro and in vivo models as well as its role in dysregulating PR function will be the focus of this review. For a detailed review on progesterone action in the endometrium, as well as endometrial diseases, the reader is directed to a recent review [8] .
PROGESTERONE ACTION IN THE ENDOMETRIUM
The requirement of progesterone and the many changes that occur in the uterus in response to this hormone are well documented [8, 9] . Progesterone relies on the priming effect of estrogen to remodel the endometrium during the luteal phase of the menstrual cycle. Such transformation includes morphological and biochemical changes of the glands and stroma, from a proliferative to a secretory phenotype [2] . The glands develop large lumens, the stroma becomes edematous with increased blood vessel permeability, cells become transformed, and the tissue takes on a more decidual phenotype, all to support the implantation and development of an embryo. If there is no pregnancy, levels of estrogen and progesterone decline because of the regression of the corpus luteum, causing the upper two thirds of the endometrium to be shed.
Progesterone action in the uterus has been studied for over eight decades and as technologies have become more sophisticated, more information on the regulation and action of progesterone through its receptor has been uncovered. Many of the details can be found in recent review articles [4, [8] [9] [10] [11] ]. There are two major isoforms of PR, PRA and PRB [12] [13] [14] [15] , which have distinct transcriptional activities [16] [17] [18] [19] [20] [21] [22] [23] . PRA and PRB are expressed in both the epithelial and stromal cells of the human endometrium, with differential expression during the different phases of the menstrual cycle [24] [25] [26] [27] . Other cell types in the endometrium express PR, such as endothelial cells of venules and lymphatics as well as smooth muscle cells and/ or pericytes [28] . Progesterone acts on all cell types that express PR, and important paracrine factors are necessary for the physiological effects observed, such as proliferation and differentiation. These have been demonstrated with a series of tissue recombination studies and transgenic mice [29] [30] [31] , and in in vitro coculture systems of both epithelial and stromal cells of the endometrium [31] [32] [33] [34] [35] [36] .
PROGESTERONE RESISTANCE IN ENDOMETRIOSIS AND ENDOMETRIAL CANCER
Endometriosis is a disease that affects women of reproductive age and is characterized by endometrial-like tissues embedded to organs outside of the uterine cavity [37, 38] . This causes severe pain and has been associated with infertility. This disease is dependent on estrogen, and also has been described to be progesterone resistant because of the blunted or inadequate response to progesterone of both the eutopic and ectopic endometrial cells and tissue [39] [40] [41] . Levels of PR are low in endometriotic tissues and cells [42] , expression of progesterone target genes is blunted [43] [44] [45] , and decidualization is inadequate [41, 43, 45] . Ectopic lesions persist throughout the menstrual cycle.
Type I endometrial carcinomas account for approximately 70%-80% of endometrial cancer cases and typically arise from the glandular component. These tumors are associated with chronic estrogen exposure and insufficient countering progesterone. Type I endometrial tumors generally are detected early and prognosis is favorable. ER and PR are generally expressed in the tumors, although receptor levels decline with increasing severity of the disease. Progestins can be used in the clinic as a fertility-sparing option, for patients with multiple comorbidities who are poor surgical candidates, and as palliative treatment for recurrent endometrial cancer. Progestins promote an atrophic endometrium and are effective for treatment of endometrial hyperplasia in 80%-90% of patients [46] [47] [48] [49] [50] [51] [52] . This percentage decreases with endometrial cancer, however, with a complete response observed in approximately 50% of patients [50, [52] [53] [54] [55] . Moreover, the risk of recurrence is high, requiring close monitoring or ultimately surgery. In patients with advanced or recurrent endometrial cancer, the response to progestins declines further, with about a 15%-20% response rate [56, 57] .
The reasons for the lack of response to progestins in endometrial cancer and endometriosis are not entirely clear. Studies point to possible epigenetic silencing of the PR gene. Methylation of the PR promoter has been demonstrated in endometriosis [58] [59] [60] and endometrial cancer [61] , which would result in the decreased levels of PR found in the diseased tissues. The causes for epigenetic silencing of PR are not known. Inflammation and oxidative stress have long been implicated in epigenetic changes in DNA and chromatin remodeling proteins. The inflammatory nature of endometriosis [62] [63] [64] [65] and obesity [66] , the latter being a significant risk factor for endometrial cancer, may be one driver of PR gene methylation and decreased expression. In support of this, it has been shown that prolonged treatment of endometriotic cells with tumor necrosis factor a resulted in partial methylation of PR [67] . The role of inflammation in progestin resistance in endometriosis has recently been reviewed [66] . There are other mechanisms by which PR is downregulated leading to progesterone resistance, including posttranslational modifications of PR that promote increased protein degradation, as well as loss of important coregulators resulting in suboptimal PR activity, which are highlighted in this review.
ROLE OF AKT IN THE ENDOMETRIUM
To our advantage, the PI3K/AKT pathway has been studied in intricate detail and the major kinases in this pathway have been identified [68, 69] . Receptor tyrosine kinases are activated upon ligand binding (i.e., growth factors) and subsequently phosphorylate PI3K directly or indirectly through the interaction of multiple adapter proteins. PI3K converts intracellular PtdIns-4,5-P2 (PIP2) to PtdIns-3,4,5-P3 (PIP3). PTEN antagonizes PI3K activity by dephosphorylating PIP3, leading to its conversion back to PIP2. In the absence of PTEN, the PIP3 lipid product predominates, leading to activation of PI3K-dependent downstream signaling pathways. AKT is one of the primary kinases downstream of PI3K. Once the PIP3 lipid product predominates, AKT translocates to the plasma membrane, where it binds to PIP3, allowing it to be phosphorylated and activated by PDK1 and mTORC2 [70, 71] .
Early studies in the rodent uterus demonstrated that AKT is a survival factor of endometrial cells [72] [73] [74] . In human endometrial stromal cells, phospho-AKT levels decreased as cells decidualized [41, 75] , and it has been shown that activation of AKT by insulin decreased expression of IGFBP1, a marker of decidualization [76] . Rapid activation of AKT by estradiol and progestins has been shown in endometrial stromal cells, resulting in proliferation and migration of endometrial stromal cells [77] [78] [79] [80] [81] .
AKT PATHWAY IN ENDOMETRIAL CANCER

PTEN/PI3K/Akt Alterations in Endometrial Cancer
Among the common genetic alterations in type I endometrial cancers, such as alterations to MSI (microsatellite instability), KRAS, and CTNNB1 [82, 83] , PTEN is the most frequently mutated gene in type I endometrial cancers, and has been reported to be mutated in up to 83% of endometrioid lesions and 55% of precancerous hyperplastic lesions ( [85, 86] . Rare activating mutations to the PH domain (E17K) of AKT1 have been reported to occur in up to 2% of primary endometrial carcinoma samples [87] . Additionally, a recent study has indicated that heterozygous PTEN mutations frequently cooccur with PIK3CA mutations at a rate of 61% and PIK3R1 mutations at a rate of 39% [88] . Finally, whole-exome sequencing and multi-platform analysis of endometrial carcinoma samples for the Cancer Genome Atlas has indicated that up to 93% of endometrial tumors with endometrioid histology have some aberration in the PTEN, PIK3CA, and PIK3R1 genes [5] . Furthermore, of all the cancers studied by the Cancer Genome Atlas, the PI3K/AKT pathway is the most frequently mutated in endometrial cancer. Taken together, the most commonly mutated pathway in type I endometrial cancers is the PI3K/AKT pathway, indicating the importance of this signaling axis in the pathogenesis of endometrial cancer as well as the potential for PI3K/AKT targeted therapy.
AKT in Endometrial Cancer Cell Signaling
Since its discovery, AKT has emerged as a critical signaling molecule in a number of physiological processes, and as a result, it is often dysregulated in disease states. AKT plays a central role in tumorigenesis; it regulates a number of cellular processes including metabolism, cell cycle, apoptosis, proliferation, angiogenesis, survival, and protein synthesis [89] . Key substrates of AKT include mTOR, GSK3a/b, FOXOs, BAD, IKKa, p21Cip1, p27Kip1, TSC2, MDM2, PRAS40, eNOS, ER, and androgen receptor (AR). These factors play significant roles in mediating cell survival, growth, apoptosis, and proliferation. Because of the frequency of mutations within the PTEN/PI3K/AKT pathway in endometrial cancer, the AKT pathway has emerged as a critical oncogenic signaling mediator.
LEE AND KIM
The role of AKT in endometrial cancer has been studied mostly in the context of the endometrial epithelium. Recent studies have confirmed that Pten loss or Akt activation in the endometrial epithelium, and not the stroma, is required for the initiation of endometrial cancer [90] . In this study, an in vivo regeneration system was used in which dissociated neonatal mouse endometrial stromal cells and adult endometrial epithelial cells were combined and engrafted in mice. The epithelial cells were then infected with constitutively active Akt lentivirus. Constitutively active Akt initiated endometrial hyperplasia and well-differentiated adenocarcinoma in grafted tumors, whereas wild-type epithelium did not exhibit any remarkable pathology. Investigators repeated the experiment with Pten loss and found similar results to constitutively active Akt [90] . To further confirm the role of Pten in the epithelium, Daikoku et al. [91] conditionally deleted Pten in endometrial stroma and myometrium but not in the epithelium. Pten deletion in the stroma and myometrium was not sufficient to initiate endometrial cancer in mice up to 5 mo of age, confirming that PTEN/PI3K/Akt signaling in the epithelium is critical for the initiation of endometrial cancer.
An important downstream substrate of AKT in endometrial cancer is the transcription factor FOXO1. FOXO1 belongs to the FOXO family of tumor suppressors that play key roles in cell proliferation, metabolism, and survival. AKT-dependent phosphorylation of FOXO1 results in its cytoplasmic sequestration, where it can then be ubiquitinated and ultimately degraded by the proteasome [92] . In endometrial cancer cells with high AKT activity, FOXO1 protein levels are lower than in endometrial cancer cells with low AKT activity [93, 94] . In endometrial cancer cells, FOXO1 plays a significant role in the regulation of cell survival and proliferation. AKT inhibitor (API59) and carboplatin treatments can synergize to further increase apoptosis in Ishikawa endometrial cancer cells [95] . Additionally, treatment with both API59 and carboplatin induced FOXO1 nuclear accumulation, and overexpression of constitutively active FOXO1 with carboplatin treatment synergistically increased apoptosis similarly to API59 and carboplatin treatments. Moreover, constitutively active FOXO1 overexpression both decreased cell proliferation and increased apoptosis in Ishikawa cells in the presence of progestin [94] . Altogether, it is apparent that FOXO1 is a critical downstream target of AKT signaling in endometrial cancer.
Akt in Endometrial Cancer Mouse Models
Given the prevalence of mutations in the PTEN/PI3K pathway in endometrial cancer, a number of mouse models featuring PTEN loss have been developed for the study of endometrial cancer in vivo. Mice with global haplodeficiency of Pten develop a number of solid tumors in prostate, endometrial, thyroid, colon, and skin tissues in addition to developing leukemia and T-cell lymphoma [96] [97] [98] . In this mouse model, female Pten heterozygous mice develop focal endometrial lesions by approximately 9 mo of age. Chen et al. demonstrated that loss of Akt1 in Pten þ/À mice was sufficient to inhibit the development of endometrial tumors, confirming that Akt signaling is the primary driver of tumorigenesis in the Pten þ/À mouse model [96] . Additionally, several conditional endometrial cancer-specific mouse models have been developed utilizing the PR Cre/þ mouse to drive endometrial-specific deletion of key tumor suppressor genes. Daikoku et al. [99] first established the Pten lox/lox /PR Cre/þ mouse model in which Pten is conditionally deleted in the uterus. These mice developed endometrial carcinoma as early as 1 mo of age and endometrial carcinoma with myometrial invasion at 3 mo of age. These mice demonstrated elevated phospho-Akt levels as well as increased Ki67 positivity in the endometrial epithelium when compared to wild-type mice. In the same study, p53 was also conditionally deleted from the endometrium; however, there was no discernable phenotype and histology was normal through 5 mo, once again confirming the importance of the PTEN/PI3K/Akt pathway in endometrial cancer.
In recent years, the Pten lox/lox /PR Cre/þ mouse model has been combined with loss of additional key tumor suppressor genes or addition of oncogenic drivers to demonstrate acceleration of endometrial cancer progression. Combinatorial loss of Pten and oncogenic Kras G12D mutation in the endometrium demonstrated accelerated endometrial cancer development when compared to single mutations in either gene [100] . These mice also exhibit advanced mortality and loss of steroid hormone receptor expression. Taken together, conditional loss of Pten is sufficient to induce endometrial carcinogenesis in mouse models, and the development of endometrial cancer can be accelerated with additional aberrations to key tumor suppressors or oncogenes.
One drawback to the Pten lox/lox /PR Cre/þ mouse model is that the expression of Cre is limited to the spatial and temporal regulation of the PR promoter. The PR promoter is active in the endometrial epithelial and stromal compartments, as well as the myometrium, oviduct, ovary, and mammary glands. Additionally, PR is expressed early in development, and Pten lox/lox / PR Cre/þ mice lose Pten expression as early as 10 days. To circumvent these issues, it has been shown that Adenoviral-Cre administration directly into the uterine lumen can efficiently delete Pten in the endometrial epithelium of adult Pten lox/lox mice [102] [103] [104] . Joshi and Ellenson [103] observed that approximately 50% of mice injected with Adenoviral-Cre developed either complex atypical hyperplasia or invasive carcinoma and that these tumors resembled sporadic focal endometrial cancers similar to what is seen in humans. Recently, using this Adenoviral-Cre approach, Cheng et al. [104] demonstrated that dual loss of Pten and Lkb1 in the endometrial epithelium resulted in accelerated development of advanced poorly differentiated endometrial tumors. Furthermore, these tumors exhibited sensitivity to inhibitors of mTOR, which lies downstream of both the LKB1/AMPK and PTEN/ PI3K/Akt pathways. Finally, investigators demonstrated that ectopic expression of LKB1 in endometrial cancer cells AKT AND PR IN ENDOMETRIAL DISEASES deficient in both PTEN and LKB1 restored sensitivity to PI3K inhibitors. These findings, taken together, indicate that the PTEN/PI3K pathway remains a significant pathway in the development of endometrial cancer and remains an attractive target for therapeutic intervention.
AKT PATHWAY IN ENDOMETRIOSIS
A relatively small number of studies have reported activation of the AKT pathway in endometriosis [6, 7, 41, [105] [106] [107] [108] [109] . Cinar et al. [6] studied ectopic and matched eutopic tissues from 15 patients from various stages of the menstrual cycle and found higher levels of p(Ser473)-AKT in endometriosis tissues. Zhang et al. [105] studied endometrioma tissues from 26 patients and found that PTEN levels were low in the epithelial cells of both the eutopic and ectopic tissues, with concomitant increase in pAKT levels. Leconte et al. [106] obtained biopsies of eutopic endometrium and deep infiltrating endometriotic nodules from 18 patients and found increased pAKT in epithelial and stromal cells from these tissues compared to normal endometrial tissues. Honda et al. [107] showed an increase in pAKT in ovarian endometriomas in two patients. Yin et al. [41] demonstrated, in endometriotic lesions from the adnexa from six patients, that p(Ser473)-AKT levels are higher compared to normal endometrial tissues. Furthermore, endometrial stromal cells from ovarian endometriomas maintained increased p(Ser473)-AKT levels in culture.
No reports have demonstrated any significant incidence of mutations in the PTEN or PIK3CA genes. Rather, the increased AKT activation in endometriotic tissues is most likely due to increased levels of growth factors, cytokines, and hormones that accompany the inflammatory and hormonal nature of the disease [110] [111] [112] [113] [114] . Endometriosis is associated with a highly inflammatory environment within the peritoneum [62] . The presence of ectopic lesions triggers an immune response resulting in the secretion of cytokines and chemokines [63] [64] [65] . Along the same lines, an increase in oxidative stress and inflammation promotes the production of reactive oxygen species, which have been shown to decrease activity of phosphatases, including PTEN [115] . Endometriotic tissues synthesize and secrete estradiol [116] , which can also activate AKT in a nongenomic manner [117, 118] . Estradiol can also increase the production of cytokines [119] , creating a potential positive feedback circuit and augmenting the inflammatory environment. Additional studies are required to demonstrate the direct activation of the AKT pathway by these cytokines and hormones in endometriosis.
The role of AKT in endometriosis has been studied in the context of decidualization and survival. Reports consistently demonstrate that decidualization is blunted in the eutopic and ectopic tissues and cells in endometriosis [120] [121] [122] [123] . Moreover, the insufficient decidualization response is observed in cultured cells in response to decidualization stimuli, progestins, and cAMP. Overactive AKT in endometriotic stromal cells also attenuates decidualization through its downstream target FOXO1. This transcription factor has been shown to be important for adequate decidualization of endometrial stromal cells [124] [125] [126] [127] [128] . In endometriotic stromal cells, levels of FOXO1 were lower because of heightened AKT activity. Inhibition of PI3K and AKT increased nuclear FOXO1 and IGFBP1 expression in response to treatment with medroxyprogesterone acetate and dibutyryl cAMP [41] , supporting that increased AKT activity is sufficient to blunt the decidualization response.
AKT promotes survival of endometriotic cells. Inhibition of this pathway led to decreased proliferation and viability both in vitro and in mouse models [7, 108] . Leconte et al. [106] reported similar observations upon treatment of endometriotic cells with the mTOR inhibitor temsirolimus supporting the role of the AKT pathway in cell proliferation and survival. A sesquiterpene lactone, costunolide, inhibited the activation of Akt and nuclear factor kappa B and the expression of antiapoptotic factors B-cell lymphoma-extra large and Xlinked inhibitor of apoptosis protein in endometriotic cell lines [129] . These studies support the role of AKT in promoting proliferation and survival of endometriotic cells. Recently it was demonstrated that AKT promotes the establishment of endometriosis in a novel mouse model [108] . The Pten lox/lox / PR Cre/þ bigenic mouse described above develops endometrial carcinoma within 1 mo of age. The heterozygous mice, however, do not develop endometrial carcinoma until much later and are cancer free in the first 2 mo of life [108] . In the Pten þ/À
/PR
Cre/þ mice, autologous implantation of uterine tissue fragments into the peritoneal cavity resulted in a significant increase in the number of ectopic lesions formed. To demonstrate the role of AKT in the establishment of disease, these mice were treated with an AKT inhibitor, which dramatically decreased the number of ectopic lesions in these mice. This model demonstrated that an overactive AKT pathway in the endometrium is permissive to attachment and survival of uterine tissues at ectopic sites in the peritoneum. Given that Pten is deleted in uterine tissues and not at the ectopic organ sites that do not express PR, this demonstrates that aberrance in the endometrium promotes establishment of lesions.
INFLUENCE OF AKT ON PR ACTION
Given the prevalence of aberrations within the PI3K/AKT pathway in endometrial cancer and endometriosis, it has been inferred that the PI3K/AKT pathway may be involved in promoting progestin resistance. Although the effect of AKT on PR action is an area of investigation that is emerging, there is supportive evidence that these two distinct pathways converge and interact in these cells. Here, we examine the role of AKT in the regulation of other steroid hormone receptors in order to gain further insights into the relationship between AKT and PR (Fig. 1) . Many of these data were generated from cancer cells, where AKT is overactive and provides a solid basis for extrapolating mechanisms to other cancers and diseases such as endometriosis.
AKT-Steroid Hormone Receptor Crosstalk
Estrogen receptor. AKT has been shown to be a key determinant in the regulation of steroid hormone receptors in cancer. The relationship between AKT and ER has been studied extensively, with many studies focusing on AKT and ERa. It has been shown that AKT-mediated phosphorylation of ERa at Ser167 enhanced ERa transcriptional activity and transcription of ERa target genes even in the absence of ligand [130] . In the same study, Campbell et al. [130] found that constitutively active AKT protected MCF-7 breast cancer cells from tamoxifen-induced apoptosis, implicating a role for AKT in promoting tamoxifen resistance. Furthermore, AKT-mediated phosphorylation of ERa at Ser167 is sufficient to increase ERa protein levels in Hek 293T cells through blocking proteasome-dependent degradation [131] . Additionally, activation of Akt was demonstrated to increase ERa transcriptional activity as well as increase levels of pSer167 ERa in uterine samples from the PTEN þ/À mouse model that develops endometrial lesions [132] . Taken together, AKT-dependent phosphorylation of ERa at Ser167 appears to play a prominent LEE AND KIM role in conferring its transcriptional activity and protein stability in multiple models of cancer. The AKT-ER relationship is not only limited to site-specific phosphorylation by AKT; studies have also indicated that increased AKT activity may alter ERa recruitment on a genome-wide scale. Using ChIP-on-chip, it was reported that constitutively active AKT signaling is sufficient to alter genome-wide ERa binding, with the finding that approximately 40% of ERa binding sites were unique to MCF-7 constitutively active AKT cells when compared to the parental MCF-7 cells [133] . Additionally, investigators found that constitutively active AKT is sufficient to alter secondary estrogen target gene expression through E2F family members. In addition to the regulation of ERa, AKT has also been shown to play a role in the regulation of ERb. Sanchez et al. [134] demonstrated that Akt is able to phosphorylate mouse ERb within its hinge region at the Ser255 residue, and this phosphorylation is sufficient to inhibit ERb transcriptional activity through inhibiting its interaction with CBP, a known cofactor of ERb. Increasing evidence suggests that AKT signaling may play roles in mediating endocrine therapy resistance in patients. Several studies have shown that high levels of phospho-Akt correlated with increased relapse and death in ERa-positive tamoxifen-treated breast cancer patients [135] [136] [137] [138] . Altogether, the data suggest that phospho-Akt could be a useful prognostic factor in the treatment of breast cancer patients with endocrine therapies.
Androgen receptor. Like ER, the relationship between AR and AKT has been studied in detail. It has been shown that AKT can directly phosphorylate AR at Ser213 and Ser791 residues and these phosphorylation events reduce AR transactivation and expression of AR target genes [139, 140] . In addition to transactivation of AR, it has been determined that AR phosphorylation at Ser213 and Ser791 reduces AR protein stability [141] . In the study, investigators established that wildtype AR, AKT, and MDM2 form a complex, and this complex formation is abolished in phosphodeficient mutant AR Ser213A/Ser791A. Furthermore, the phosphodeficient mutant AR Ser213A/Ser791A demonstrated decreased ubiquitination and subsequent proteasomal degradation when compared to wild-type AR. Additionally, AKT-dependent phosphorylation of Ser213 and Ser791 residues is sufficient to decrease AR ligand binding. Palazzolo et al. [142] utilized an AR phosphomimetic mutant (S213D/S791D) and demonstrated that the phosphomimetic AR exhibited decreased protein stability, nuclear translocation, and ligand binding. Although AKT-dependent phosphorylation plays an important role in the AKT-AR relationship, numerous studies have shown that AKT can influence AR independently of phosphorylation. Using an in vivo prostate regeneration model system, Xin et al. [143] demonstrated that AKT and AR synergize to increase prostate epithelium growth but that AKT-dependent AR phosphorylation at Ser213 and Ser791 is not required for this synergy. 
AKT AND PR IN ENDOMETRIAL DISEASES
Therapeutically, AR remains an attractive target for the treatment of prostate cancers. For prostate cancer patients with advanced or metastatic disease, androgen deprivation therapy is the current standard treatment [144] . However, even with continuous androgen deprivation therapy, the majority of cases develop resistance and progress to castration-resistant prostate cancer (CRPC) [145] . It has been suggested that AR may crosstalk with the PI3K/AKT pathway to stimulate the growth of CRPCs. Recent work in the area of AR-AKT crosstalk has indicated that these pathways regulate each other through complex reciprocal feedback inhibition mechanisms in CRPC. Carver et al. [146] demonstrated that AR transcriptional activity is decreased in prostate tumors with PTEN loss and inhibition of PI3K signaling restores the AR transcriptional response. Also, in the same study, it was demonstrated that AR regulates AKT activity through the regulation of its target gene, FKBP5. FKBP5 is a chaperone for the AKT phosphatase, PHLPP, and thus increased FKBP5 expression stabilizes PHLPP and negatively regulates AKT activation. Additionally, Mulholland et al. [147] further confirmed the reciprocal feedback mechanism between AKT-AR in CRPC. In the study, they utilized the Pb-Cre þ /Pten L/L prostate cancer mouse model to demonstrate that PTEN loss leads to decreased AR transcriptional activity through the regulation of AR cofactors EGR1, c-Jun, and EZH2. Moreover, they also identified FKBP5 as the critical factor involved in the AR-dependent inhibition of AKT signaling. The data suggest that combinatorial PI3K/AKT inhibition and androgen deprivation therapy may be more effective than single-agent administration for the treatment of CRPC. In this vein, preclinical testing of combinatorial PI3K/AKT inhibitors and antiandrogens has thus far demonstrated greater efficacy than either agent alone in mouse models and human xenograft models of CRPC [146, 148] .
AKT-PR Crosstalk
Early studies on the crosstalk between PR and members of the AKT pathway were done in endometrial stromal cells undergoing decidualization. Transcriptional activation of decidual-specific genes required both PR and the forkhead transcription factor FOXO1 that is a direct target of AKT [127] . PR and FOXO1 coimmunoprecipitated in endometrial stromal cells and influenced each other's transcriptional activity [125] . In endometrial cancer cells, FOXO1 potentiated PR transcriptional activity in that constitutively active FOXO1 overexpression decreased both cell proliferation and increased apoptosis in Ishikawa cells in the presence of progestin [94] . Kyo et al. [149] demonstrated that AKT activity is sufficient to limit progestin-induced inhibition of endometrial cancer cell proliferation through the restriction of FOXO1 nuclear accumulation. Given that FOXO1 levels are dramatically lower in endometrial cancer [93, 94] , this may be one mechanism by which progestin responsiveness diminishes because of increased AKT activation.
Recent studies have indeed suggested that AKT may play a role in promoting progestin resistance. Unlike ER and AR, the effects of AKT on PR have not been investigated in detail, although this is an emerging area of interest. Reports have shown that Akt is sufficient to downregulate PR protein expression levels in breast cancer cells, endometrial cancer cells, and endometriotic stromal cells [150, 151] . In endometriotic stromal cells, inhibition of AKT increased total and nuclear levels of PR. AKT inhibitor and progestin combinatorial treatment decreased cell viability and increased apoptosis in cells in culture and xenografts grown in mice [7] . In endometrial cancer cells, inhibition of the PI3K/AKT pathway increased PR protein levels as well as modulated expression of PRB target genes BIRC3 and PDK4 [151, 152] . Pant et al. [151] demonstrated that combinatorial AKT inhibitor and progesterone treatments synergistically decreased endometrial cancer cell viability as well as growth of xenografts. Additionally, utilizing endometrial cancer cells that had developed progestin resistance, Gu et al. [153] demonstrated that combinatorial PI3K inhibition and progestin treatments synergized to decrease cell viability and xenograft growth. In ovarian cancer cells, PR regulated FOXO1 expression, and PR and FOXO1 also cooperated together to activate genes that encode the senescence-associated cell cycle inhibitors, such as p15iNK4b, p16iNK4a, p21Cip1, and p27Kip1 [154] . Similar to what was previously demonstrated [94] , progestin response was mediated through PRB and attenuated upon FOXO1 knockdown.
Results of a clinical trial were published for women with advanced or recurrent endometrial carcinoma treated with a combination of the mTOR inhibitor temsirolimus and hormonal therapy [155] . Out of 71 patients, 21 were treated with the combination treatment; however, this treatment was terminated early because of an excess of venous thrombosis observed in patients. This study concluded that the combination of megestrol acetate, tamoxifen, and temsirolimus therapy did not enhance the activity of temsirolimus. Additional stratification of patients according to mutational status and hormone receptor status will be necessary to determine which patients will benefit from such targeted combinatorial therapies.
The data thus far demonstrate that the effects of AKT on progesterone action are significant. As progesterone resistance is a clinically important problem, a deeper understanding of the pathways and mechanisms of AKT and PR crosstalk would improve how targeted therapeutic interventions are developed. An intense investigation on the role of AKT in the molecular actions of PR is underway.
CONCLUSIONS AND FUTURE DIRECTIONS
Overactivation of the AKT pathway occurs in numerous diseases, especially in the field of cancer. Endometrial cancer is unique in that the most prevalent mutations are those within the PI3K/AKT pathway. Endometriosis is also characterized by an overactive AKT pathway, likely because of the inflammatory and hormonal nature of the disease rather than mutations in PTEN or other members of the pathway. As a result, other pathways, including the MAPK pathway, are overactive [122] . Interestingly, specific genes and processes are regulated by AKT that are not regulated by MAPK in endometriotic stromal cells [41, 122] , which may be because of how the cells are programmed or epigenetically modified.
Given the significant role that progesterone plays in the endometrium, resistance to this hormone has far-reaching consequences. What remains to be done is to characterize phosphorylation events on PR by AKT and to elucidate molecular mechanisms by which AKT is influencing PR transcriptional function. Moreover, it would be interesting to know whether PR regulation by AKT is different between the endometrial cancer cells, which are of epithelial origin, and the endometriotic cells, which are mostly stromal cells. Additionally, the Pten þ/À
/PR
Cre/þ endometriosis mouse model is ideal to investigate the role of Akt in progesterone action in the uterus and how the use of AKT inhibitors can be used to overcome progesterone resistance in endometriosis. Similarly, in order to specifically study the role of AKT on progesterone resistance, Akt transgenic mouse models could be considered.
LEE AND KIM
For example, the role of the different AKT isoforms (Akt1, Akt2, Akt3) have been shown to have distinct roles in tumor initiation and progression [96, 156, 157] and therefore could be studied in the context of progesterone function in the uterus. Also, the constitutively active myristoylated Akt transgenic mice [158] are another alternative to determine the role of AKT on progesterone action. Whether the presence of ectopic lesions will affect fertility in the transgenic mice and whether combinatorial AKT inhibitor/progestin treatments will improve fertility are critical questions for which future studies need to be performed.
As mechanisms associated with AKT/PR crosstalk are unraveling, this begins the conversation of using AKT inhibitors for the treatment of endometriosis. This nonhormonal therapeutic option is a promising one that should be considered. One unique feature of the female reproductive tract is its anatomical accessibility for localized drug delivery that would minimize the systemic concentrations and, as a result, reduce side effects of drugs. With regards to endometrial cancer, increasing sensitivity to progestins, especially in advanced and recurrent disease, is an attractive option. Currently, there are a number of targeted biologics that are in clinical trials for advanced and recurrent endometrial cancer, but nothing that is in current practice for treatment of endometrial cancer aside from chemotherapeutics. With a strong biological basis and understanding of the disease, as well as stratifying patients depending on specific properties of the tumors such as mutational status and receptor expression, response rates to AKT pathway inhibitors or in combination with progestins and chemotherapies will drastically improve.
To date, much information is available with regards to PI3K/AKT signaling and in the area of progesterone action as two independent fields of study. Merging the two pathways together to study their interaction in a disease setting not only is a novel approach but is biologically relevant with a promising potential for clinical application.
